The Narrative Frays for Theranos and Elizabeth Holmes
“This isn’t how you introduce technology that claims to be groundbreaking and revolutionary in the health care field,” said Michael Cherny, an analyst at the investment bank Evercore Partners who was an early and vocal skeptic about many of Theranos’s claims.
“Every other person goes through some level of peer review,” Mr. Cherny told me this week. Theranos “decided to shun that approach.”
“In my view,” he said, “that calls into question what’s under the hood of the platform.”
Click here to read more from this October 29, 2015 New York Times article by James B. Stewart.